Skip to content
DataLookout
Menu

NCT07667829

Vasopressor Agents in Pulmonary Hypertension Crisis

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 15 words
    • Start date changed from estimate of Jun 2026 to Aug 19, 2026
    • Site details revised at 3 of 3 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

All-cause mortality within 28 days
Timeframe: 28 days after enrolment

Secondary (7)

Haemodynamic parameters
Severe arrhythmia (ventricular tachycardia, ventricular fibrillation)
Adverse effects of vasopressors
Arterial Blood Gas Analysis
Vital Signs
Show 2 moreShow less
BNP or NT-proBNP
Echocardiographic parameters

Arms and interventions

Norepinephrine groupExperimental

The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

Dopamine groupExperimental

The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min.

Epinephrine groupExperimental

The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (increase or decrease) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

Drugs: Norepinephrine, Dopamine, Epinephrine

Sites

3 sites in 1 country